Oops! It appears that you have disabled your Javascript. In order for you to see this page as it is meant to appear, we ask that you please re-enable your Javascript!

Rishat (Richat) Abbas Borhan выдающийся уйгурский учёный

Кандидат фармацевтических наук, разработал новые препараты для лечения различных заболеваний, имеет несколько патентов и несколько десятков научных публикаций его исследований, его исследования цитировали 2295 раз.
В сентябре 1994 году получил степень кандидата фармацевтических наук (Фармакокинетика и метаболизм лекарственных средств), Отдел фармацевтики и фармацевтической химии, в The Ohio State University, Columbus. 
Последипломные исследования:
  1990- 1994:  «разработка и валидация физиологически обоснованных фармакокинетических моделей для описания поглощения, распределения, метаболизма и выделения трихлорэтилена и его метаболитов (хлоралгидрат, трихлорэтанол, трихлорэтанол глюкуронид, трихлоруксусная кислота и дихлоруксусная кислота) . В отделении токсикологии, Лаборатории / Геоцентры Армстронга, Военно-воздушная база Райта-Паттерсона, Дейтон, Огайо.


с 1996 по 2000 год:

Фармакокинетик, старший фармакокинетик / руководитель, PK / PD, метаболизм лекарственных средств и оценка безопасности, Otsuka America Pharmaceutical, Inc. Rockville, Maryland. Участвовал в исследованиях и разработке новых препаратов для лечения сердечно-сосудистых заболеваний и заболеваний центральной нервной системы. Способствовал развитию Abilify (арипипразол, препарат ЦНС для лечения шизофрении) и PLETAL (cilostazol, сердечно-сосудистый препарат для лечения перемежающейся хромоты).

С 2000 по 2002 год:

Научный сотрудник / директор, Biopharmaceutics, Emisphere Technologies, Inc. Tarrytown, New York, Проводил доклинические и клинические фармакокинетические, метаболические и фармакодинамические исследования и способствовал развитию перорального инсулина для лечения диабета, перорального гепарина для сердечно-сосудистых заболеваний и пероральный кромолин для лечения астмы. Разработал, провел и проанализировал устные клинические испытания перорального инсулина и перорального кромолина, а также первоначальную оценку перорального инсулина у пациентов с диабетом II типа. Применяется в США для «терапии оральным инсулином» и для «Препаратов для перорального введения кромолина натрия».

с 2002 по 2004 год:

Ассоциированный клинический директор / клинический фармаколог, отдел клинической фармакологии, глобального развития лекарственных средств, Hoffmann-La Roche Inc., глобальная исследовательская управляющая фармацевтическая и диагностическая компания, Nutley, Нью-Джерси.
Проводил клинические фармакокинетические / фармакодинамические и фармакологические исследования метаболизма и способствовал развитию противораковых препаратов (TarcevaTM – пероральный нецитотоксический препарат для лечения местнораспространенного или метастатического рака легких), диабета (для диабета типа II) и астмы.

с 2004 года по настоящее время. 

Директор / ведущий исследователь отдела клинической фармакологии, трансляционной медицины, исследований и разработок в области глобальных наркотиков, Wyeth Research, Отвечает за проведение клинических фармакокинетических и фармакодинамических исследований и разработку противораковых лекарств для различных опухолей (рак молочной железы, рак легкого, колоректальный рак, рак поджелудочной железы, меланому, рак головы и шеи, рак яичников и хронический миелолейкоз). Wyeth Research (Collegeville, Pennsylvania), подразделение Wyeth, имеет ведущие продукты и исследования в области женского здравоохранения, сердечно-сосудистых заболеваний, центральной нервной системы, воспаления, трансплантации, гемофилии, онкологии, вакцин и пищевых продуктов. Wyeth является одной из крупнейших в мире научно-исследовательских крупных фармацевтических и медицинских компаний.
Является обладателем наград:

1)Best Abstract (2001) – за разработки в сфере диабета.

2) Best Paper in the Field of Risk Assessment (1999) – за лучшую исследовательскую работу в области оценки риска, от « Общества токсикологии. 
3)Science and Technology Achievement Award – от Министерства обороны США

4) Scientific Achievement Award- от департамента военно-воздушных сил 

5) Graduate Research Assistant Award от The Ohio State University
Патенты:

PATENTS:
  Abbas, Richat, et al. “Oral insulin therapy”. United States Patent – 20030198666, U.S. Current Class: 424/452; 424/465; 514/3. U.S. Class at Publication: 424/452; 514/3; 424/465. International Class: A61K 038/28; A61K 009/48; A61K 009/20 

  Abbas, Richat, et al. “Formulations for Oral administration of Cromolyn Sodium” US Patenet No. 02789934.3-2123 – US0238247

Публикации:
R Abbas, Y Hijazi, JP Tang, LM Renzetti, A Rames and H Welker. Effect of R411, a Dual a4/b1-a4/b7 Integrin Antagonist Being Developed for Asthma, on the Activities of the Major Drug Metabolizing Enzymes After Oral Administration in Healthy Subjects. Clinical Pharmacology & Therapeutics, Vol. 75, No.2, p-79, 2004.

Kidron M.; Dinh S.; Menachem Y.; Abbas R.; Variano B.; Goldberg M.; Arbit E.; Bar-On H. A novel per-oral insulin formulation: proof of concept study in non-diabetic subjects Diabetic Medicine, April 2004, vol. 21, no. 4, pp. 354-357(4)

Richat Abbas, Scott Fettner, Myriam Riek, Sunita Bulsara, Michael Pantze, Marta Hamilton, Paul Frohna, and Ashok Rakhit A drug-drug interaction study to evaluate the effect of rifampicin on the pharmacokinetics of the EGF receptor tyrosine kinase inhibitor, TarcevaTM, in healthy subjects. Proc Am Soc Clin Oncol 22: page 137, a-548, 2003

Youssef Hijazi, PhD, Horst Welker, PhD, Albert E. Dorr, PhD, Jian-Ping Tang, PhD, Roger Blain, PhD, Louis M. Renzetti, PhD and Richat Abbas, PhD Pharmacokinetics, Pharmacokinetics, Safety, and Tolerability of R411, a Dual {alpha …

… The Journal of Clinical Pharmacology, 2004; 44:1368-1378 © 2004 American

College of Clinical Pharmacology.

C. Kapitza, E. Arbit, R. Abbas, M. Goldberg, M. Hompesch, L. Heinemann, T. Heise, Oral Insulin: Proof of concept in type 2 diabetic patients. Diabetes. 52-S.1. A37, 2003.

Ashok Rakhit, Scott Fettner, Stephen Davis, Richat Abbas, Flavio De Rosa, Ulrich Brennscheidt, Chis Twelves and Jose Baselga. Lack of pharmacokinetic interaction between erlotinib, docetaxel and capecitabine in breast cancer patients. European Journal of Cancer, Supplements, Vol. 1, No. 5, p-S115 09. 2003. 

Richat Abbas, Scott Fettner, Myriam Riek, Stephen Davis, Marta Hamilton, Paul Frohna,. Ashok Rakhit Clinical pharmacokinetics of erlotinib in healthy subjects. European Journal of Cancer Supplements; Vol. 1, No. 5, p-S168, 09. 2003.

Zhongping John Lin, Richat Abbas , Lorraine M. Rusch and Linyee Shum – Development and Validation of a Sensitive LC-MS/MS Method for the Determination of Cromolyn in Human Plasma, Journal of Chromatography B 788 (2003) 159-166, 2003.

Richat Abbas, Andrea Leone-Bay, Rajesh Agawal, Shingai Majuru, Paul Rolan, Cyril Clarke, Colin Scott, Ehud Arbit­, Robert A. Baughman – Oral Insulin: Pharmacokinetics and Pharmacodynamics of Human Insulin Following Oral Administration of an Insulin/Delivery Agent Capsule in Healthy Volunteers. Diabetes. Volume 51, A48, S. 2, 2002.

Richat Abbas, Robert A. Baughman, S. De Bruyn2, Donald Sarubbi, and Ehud Arbit – Oral Cromolyn: Pharmacokinetics of Cromolyn Sodium Delivered Orally in Healthy Volunteers. Allergy Vol. 57, S73, 338, 2002.

Richat Abbas, Rajesh Agarwal, Terry Rivera-Schaub, Andrea Leone-Bay, Kiran Chaudhary, and Robert A. Baughman – Evaluation of the Effect of Three Different Oral Heparin/SNAC Formulations on Pharmacokinetics (PK) of Heparin Following Oral Administration in Healthy Subjects. Pharm. Sci Vol. 4, No. 4, R621, 2002.

Richat Abbas, A.Chaouki Zerouala, and Robert A. Baughman. PHARMACOKINETICS (PK) AND PHARMACODYNAMICS (PD) OF SNAD/HEPARIN IN RHESUS MONKEYS. Drug Metabolism Review Vol. 33, 400, 2001.

13. Richat Abbas, Alda Pombo-Gentile, and Robert A. Baughman. Absolute bioavailability of SNAD and Pharmacokinetics of SNAD/heparin in rats Drug Metabolism Review Vol. 33, 124, 2001.
14. Lorraine M. Rusch, Richat Abbas, Catherina M. O’Shaughnessy, Liangfu Chen, and Robert A. Baughman. Interspecies Comparison of SNAC and SNAD IN VITRO PLASMA PROTEIN BINDING. Drug Metabolism Review Vol. 33, 233, 2001.
15. Catherina M. O’Shaughnessy, Lorraine M. Rusch, Richat Abbas, Liangfu Chen and Robert A. Baughman. IN VITRO EVALUATION OF SNAC INTERACTION WITH HUMAN CYP450 ISOENZYMES Drug Metabolism Review Vol. 33, 381, 2001.
16. Richat Abbas, Gregory Osgood, Terry Rivera-Schaub, James C. Kisicki, and Robert A. Baughman. A Clinical Drug-interaction Study to Evaluate Effect of Antacid Pre-treatment on the Absorption of Heparin and its Delivery Agent, SNAC, Following Oral Administration in Healthy Subjects. PharmSci Vol. 3, No. 3, ISSN 1522, 2001.
17. Richat Abbas, Andrea Leone-Bay, Terry Rivera-Schaub, Shingai Majuru, James C. Kisicki, and Robert A. Baughman. An Open-label, Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of SNAD, an Oral Heparin Delivery Agent, when Administered Orally as SNAD Tablets or Heparin/SNAD Tablets to Healthy Male Volunteers. PharmSci Vol. 3, No. 3, ISSN 1522-0893, 2001.
Abbas, R., Chow, C. P., Browder, N. J., Thacker, D., Bramer, S. L., Fu, C. H. J., Forbes, W., Odomi, M. and Flockhart, D.A. In vitro Metabolism and Interaction of Cilostazol with Human Hepatic Cytochrome P450 Isoforms. Human & Experimental Toxicology. 19(3). 178-184, 03, 2000.

Lash, L. H., Putt, D. A. Brashear, W. T., Abbas, R., Parker, J. C., and Fisher, J. W. Identification of S-(1,2-Dichlorovinyl) glutathione in the blood of human volunteers exposure to trichloroethylene J. Toxicol Environ. Health 56: 1-21, 1999.

Gu, Z., Tata, P. Zhou, D., Abbas, R., Wu, J., Lewis, N. J., and Bramer, S. L. Sensitive and specific LC-MS/MS method for the analysis of low levels of OPC-29030 and ten metabolites in human plasma and urine. Pharm. Sci. Suppl. Vol. 1, No. 1, s-189, 1998.

21. Abbas, R., Bramer, S. L., Cowart, D., Adeyemo, O. M., Kitani, M., Miyamoto, G., and Browder, N. J. Interspecies Comparison of TOBORINONE Pharmacokinetics in Rats, Rabbits, Dogs, Monkeys, and Humans. Toxicological Sciences, vol. 42, No.1-S, p216, 1998.
Adeyemo, O.M., R. Abbas, D. Sibley, R. Mailman, R. Wilcox, T. Kikuchi, T. Hirose, and N. J. Browder, OPC-14597: Unique pharmacology and receptor binding characterization studies on a novel antipsychotic agent, The Toxicologist, 42, No. 1215, p. 246, 1998

Abbas, R., Flockhart, D. A., Thacker, D., Bramer, S. L., Cowart, D., and Browder, N. J. In vitro metabolism of toborinone by human liver cytochrome P450 isoforms. Toxicology Letters, vol. 95, S1, p101, 1998.

Fisher, J.W., Mahle, D. and Abbas, R. A Human Physiologically Based Pharmacokinetic Model for Trichloroethylene and its Metabolites, Trichloroacetic Acid and Free Trichloroethanol. Toxicol. Appl. Pharm. 152, 339-359, 1998.

25. Browder, N. J., Flockhart, D. A., Thacker, D., Bramer, S. L., Cowart, D., and Abbas, R. EFFECT OF TOBORINONE ON HUMAN LIVER CYTOCHROME P450 ISOFORMS AND INTERACTION WITH THEOPHYLLINE. Toxicological Sciences, vol. 42, No.1-S, p91, 1998.
26. Fu, C. J., Abbas, R., Tata, P. N. V., Cowart, C., Bramer, S. L. AN HPLC METHOD FOR THE ANALYSIS OF TOBORINONE (OPC-18790) AND FOUR METABOLITES IN HUMAN PLASMA. Toxicological Sciences, vol. 42, No.1-S, p219, 1998.
Abbas, R. Tata, P. Bramer, S. L. Li, Y. X. Heitkamp, J. and Velagaleti, P. A SENSITIVE AND SPECIFIC CHIRAL HPLC-MS/MS METHOD FOR QUANTITATIVE ANALYSIS OF LOW LEVELS OF R(+) AND S(-) ENANTIOMERS OF OPC-41061 IN HUMAN SERUM. Pharm. Res. Vol. 14, No. 11, pp. s-360, 1997.

Abbas, R. Browder, N. J. Chow, P. Odomi, M. and Bramer, S. L. INTERSPECIES COMPARISON OF CILOSTAZOL PHARMACOKINETICS IN MICE, RATS, DOGS, MONKEYS, AND HUMANS. Pharm. Res. Vol. 14, No. 11, pp. s-360, 1997.

Moghaddam, A. P., Abbas, R., Fisher, J. W, and Lipscomb, J. C. The role of mouse intestinal microflora in the metabolism of Trichloroethylene, an In Vitro Study. Human and Experimental Toxicology. 16, 629-635. 1997. 

Abbas, R., and Fisher, J. W. A physiologically based pharmacokinetic model for trichloroethylene and its metabolites, chloral hydrate, trichloroacetate, dichloroacetate, trichloroethanol, and trichloroethanol glucuronide in B6C3F1 mice. Toxicol. Appl. Pharm. 127, 15-30, 1997.

Fu, C. J., Abbas, R. Tata, P. Chow, P. Browder, N. J. and Bramer, S. L. An HPLC method for the analysis of toborinone and four metabolites in human liver microsomal incubation solutions. Pharm. Res. Vol. 14, No. 11, pp. s-566, 1997.  

32. Abbas, R. and W. L. Hayton. A Physiologically Based Pharmacokinetic and Pharmacodynamic Model for Paraoxon in Rainbow Trout. Toxicol. Appl. Pharmacol.,145, 192-201, 1997.
Brashear. W. T., Bishop, C. T., and Abbas, R. Electrospray analysis of biological samples for trace amounts of trichloroacetic acid, dichloroacetic acid and monochloroacetic acid. J. of Anal. Tox. 21, 330-334, 1997.

Abbas, R., Seckel, C. S. and Fisher, J. W.: Determination of kinetic rate constants for chloral hydrate, trichloroethanol, trichloroacetate and dichloroacetate: a PBPK model approach. The Toxicologist, vol. 36, No. 1, 164, 1997. 

Fisher, J. W , J. D. Pleil, MacMahon, K. L. and Abbas, R.: A Physiologically Based Pharmacokinetic Model for inhalation of trichloroethylene in human volunteers. The Toxicologist, vol. 36, No. 1, 163, 1997. 

Greenberg, M.S. Abbas, R. and Fisher, J. W: A Physiologically Based Pharmacokinetic Model for inhaled trichloroethylene and its major metabolites in B6C3F1 mice. The Toxicologist, vol. 36, No. 1, 162, 1997. 

Geiss, K. T., Young, R. S., Randall, G., Kidney, J. K. Channel, S. R. and Abbas, R.: Induction of Peroxisome Proliferation-Associated genes after administration of Trichloroethylene to Mice. The Toxicologist, vol. 36, No. 1, 1185, 1997. 

Bishop, C. T., Brashear, W. T., Pollard, D. L., and Abbas, R.: Analysis of Trichloroethylene in Biological Samples. The Toxicologist, vol. 36, No. 1, 1630, 1997. 

Zhang, H. M, Brashear, W. T., Buttler, G. T., Callaghan, P. Black, R. and Abbas, R. : An Electron Capture Gas Chromatography Method for Analysis of Dichloroacetic Acid, Trichloroacetic Acid and Trichloroethanol in Biological Matrices. The Toxicologist, vol. 36, No. 1, 1631, 1997.

Lipscomb, J.C., Black, R.K., Janicki, T. J., Mahle D. A., Fisher, J. W. and Abbas, R.: Destruction of Cytochrome P450 in Vitro by Trichloroethylene: Loss of CYP3A and CYP1A Activity. The Toxicologist, vol. 36, No. 1, 1610, 1997. 

Moghaddam, A. P., Abbas, R., Fisher, J. W, Stavrou, S. and Lipscomb, J. C. Metabolism of Trichloroethylene and Trichloroacetic Acid by Mouse Gut Microflora, an In Vitro Study. The Toxicologist, vol. 36, No. 1, 1610, 1997. 

Abbas, R., Seckel, C. S., Kidney, J. K., and Fisher, J. W. PHARMACOKINETIC ANALYSIS OF CHLORAL HYDRATE AND ITS METABOLISM IN B6C3F1 MICE. Drug Metabolism and Disposition. Vol. 24, No. 12 p 1340-1346. 1996.

Moghaddam, A. P., Abbas, R., Fisher, J. W., Stavrou, S., and Lipscomb, J. C. Formation of dichloroacetic acid by rat and mouse gut microflora, an in vitro study. Biochem. Biophys. Res. Comm. 228, 639-645, 1996.

Abbas, R., Schultz, I. R., Doddapaneni, S. and Hayton, W. L. Toxicokinetics of Parathion and Paraoxon in Rainbow Trout after Intravascular Administration and Water Exposure. Toxicol. Appl. Pharmacol. 136, 194-199, 1996.

Abbas R., and Hayton W L. Gas Chromatographic Determination of Parathion and paraoxon in fish plasma and tissues. Journal of Analytical Toxicology, Vol. 20, 151-154, 1996.  

Moghaddam, A. P., Abbas, R., Fisher, J. W., Stavrou, S., and Lipscomb, J. C. Formation of dichloroacetic acid by rat and mouse gut microflora, an in vitro study. Biochem. Biophys. Res. Comm. 228, 639-645, 1996.

Abbas, R., Fisher, J. W. Black, R. K. and Garrity, B. L. A Physiologically Based Pharmacokinetic Model to Describe Disposition of Chloral hydrate and Trichloroethanol in Mice. The International Toxicologist, 33-20. 1995.

Hayton, W L, Yu. Z., Abbas, R., Vick, A. and Doddapaneni, S. Pharmacokinetics of Acriflavine in Rainbow Trout. The International Toxicologist, 89-16. 1995 

Abbas, R., Fisher, J. W., Black, R. K., Janicki, T. J. and Garrity, B. L. Disposition of Trichloroethylene and Its Metabolites in B6C3F1 Mice after Oral Administration. Pharm. Res. Vol. 12, No. 9, pp. s-338. 1995. 

Abbas, R. and Hayton, W. L., Paraoxon Tissue Distribution and AChE Inhibition in Rainbow Trout. Pharm. Res. Vol. 10, No. 10, s-365. 1993.

Doddapaneni, S., Hayton, W. L., Schultz, I. R. and Abbas, R., Tissue Distribution and Metabolic Disposition of Parathion in Rat. Pharm. Res. Vol. 10, No. 10, s-365. 1993.

Doddapaneni, S., Herzberg, U., Schultz, I.R. and Abbas, R. and Hayton, W.L., Parathion and Paraoxon Pharmacokinetics and AChE Inhibition in Rat. Pharm. Res. Vol. 9, No.10,s 268. 1992.

Abbas, R., Schultz, I. R., Doddapaneni, S. and Hayton, W. L., Pharmacokinetics of Paraoxon in Rainbow Trout. The Toxicologist, 12:1554., 1992.

 
Conference Papers:
53. G. Folprecht, J. Tabernero, L. Paz-Ares, J. Baselga, H. Cortes-Funes, E. Casado, F. Rojo, J. Vauthier, Richat Abbas, C. Zacharchuk, C. Koehne. The irreversible EGFR tyrosine kinase inhibitor EKB-569 in combination with 5-fluorouracil, leucovorin and irinotecan (FOLFIRI) in patients with advanced colorectal cancer (ACC): A phase I/IIa pharmacokinetic and serial skin and tumor pharmacodynamic study. 29th European Society for Medical Oncology (ESMO) Congress. Oct. 29 – Nov. 2, 2004, Vienna, Austria
54. R Abbas, Y Hijazi, JP Tang, LM Renzetti, A Rames and H Welker. Safety, Tolerability, and
      Pharmacokinetics of R411, a Dual a4/b1-a4/b7 Integrin Antagonist, after Oral Administration of Single-Ascending Doses in Healthy Male Subjects. Presented at the 2004 Annual Meeting of the American Academy of Allergy, Asthma and Immunology, March 19 – 23, 2004, San Francisco, CA
55. R Abbas, Y Hijazi, JP Tang, LM Renzetti, A Rames and H Welker. Effect of R411, a Dual a4/b1-a4/b7
Integrin Antagonist Being Developed for Asthma, on the Activities of the Major Drug Metabolizing Enzymes After Oral Administration in Healthy Subjects Presented at the 2004 Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics, March 24-27, 2004, Maimi Beach, FL 
56. R. Abbas, Y. Hijazi, J. P. Tang, L. M. Renzetti, A. Rames and H. Welker. Safety, Tolerability and Pharmacokinetics of R411, a Dual a4/b1 and a4/b7 Integrin Antagonist after Multiple-ascending Doses in Healthy Subjects. Preseneted at the 2004 International Conference of the American Thoracic Society. May 21-26, 2004, Orlando, FL
57. Richat Abbas, Scott Fettner, Myriam Riek, Sunita Bulsara, Michael Pantze, Marta Hamilton, Paul Frohna, and Ashok Rakhit A drug-drug interaction study to evaluate the effect of rifampicin on the pharmacokinetics of the EGF receptor tyrosine kinase inhibitor, TarcevaTM, in healthy subjects. American Society of Clinical Oncology, May 31 – June 3, 2003 Chicago, IL
58. C. Kapitza, E. Arbit, R. Abbas, M. Goldberg, M. Hompesch, L. Heinemann, T. Heise, Oral Insulin: Proof of concept in type 2 diabetic patients. 18th International Diabetes Feration Congress, Aug. 24-29, 2003, Paris, France.
59. Richat Abbas, Scott Fettner, Myriam Riek, Steve Davis, Marta Hamilton, Paul Frohna, and Ashok Rakhit. Effect of ketoconazole on the pharmacokinetics of erlotinib (TARCEVATM) in healthy adult male subjects. European Association of Clinical Pharmacology and Therapeutics (EACPT), June 24-28, 2003. Istanbul, Turkey
60. Ashok Rakhit, Scott Fettner, Stephen Davis, Richat Abbas, Flavio De Rosa, Ulrich Brennscheidt, Chis Twelves and Jose Baselga. Lack of pharmacokinetic interaction between erlotinib, docetaxel and capecitabine in breast cancer patients. Presented at the 12th annual Meeting of the Federation of European Cancer Society (ECCO-12), Sept. 21-25, 2003, Copenhagen, Denmark
61. Richat Abbas, Scott Fettner, Myriam Riek, Stephen Davis, Marta Hamilton, Paul Frohna, Ashok Rakhit. Clinical pharmacokinetics of erlotinib in healthy subjects. Presented at the 12th annual Meeting of the Federation of European Cancer Society (ECCO-12), Sept. 21-25, 2003, Copenhagen, Denmark.
62. Ehud Arbit MD, Richat Abbas PhD, Steve Dinh PhD and Michael Goldberg MD. The potential clinical implications of the pharmacokinetic profiles of insulin administered by alternate routes. Presented at the 2002 Diabetes Technologies Annual Meeting, Nov. 2002, Atlanta, GA
63. Richat Abbas, Andrea Leone-Bay, Rajesh Agawal, Shingai Majuru, Paul Rolan, Cyril Clarke, Colin Scott, Ehud Arbit­, Robert A. Baughman – Oral Insulin: Pharmacokinetics and Pharmacodynamics of Human Insulin Following Oral Administration of an Insulin/Delivery Agent Capsule in Healthy Volunteers – Presentation at the 62nd Annual Meeting American Diabetes Assciation, June 14-16, 2002, San Francisco, CA  
64. Richat Abbas, Robert A. Baughman, S. De Bruyn, Donald Sarubbi, and Ehud Arbit – Oral Cromolyn: Pharmacokinetics of Cromolyn Sodium Delivered Orally in Healthy Volunteers – Presentation at the XXI Congress of the European Academy of Allergology and Clinical Immunology, 1-5 June 2002, Naples, Italy.   
65. Richat Abbas, Rajesh Agarwal, Terry Rivera-Schaub, Andrea Leone-Bay, Kiran Chaudhary, and Robert A. Baughman – Evaluation of the Effect of Three Different Oral Heparin/SNAC Formulations on Pharmacokinetics (PK) of Heparin Following Oral Administration in Healthy Subjects. Presented at the Annual Meeting of the American Association of Pharmaceutical Scientists. Nov. 10-14, 2002, Toronto, Canada
66. Richat Abbas, Robert A. Baughman, D. de Vries, Steve Dinh and, Ehud Arbit – Pharmacokinetics of Human Insulin Delivered Orally in Healthy Volunteers – Presented at the Diabetes Technologies Meeting, (This was accepted as a best abstract and presented at Diabetes Technologies Meeting). Nov. 2-3, 2001, San Francisco, CA.
67. Richat Abbas, A.Chaouki Zerouala, and Robert A. Baughman. PHARMACOKINETICS (PK) AND PHARMACODYNAMICS (PD) OF SNAD/HEPARIN IN RHESUS MONKEYS. Presented at the 6th ISSX Annual Meeting, October 7-11, 2001, Munich, Germany
68. Richat Abbas, Alda Pombo-Gentile, and Robert A. Baughman. Absolute bioavailability of SNAD and Pharmacokinetics of SNAD/heparin in rats. Presented at the 6th ISSX Annual Meeting, October 7-11, 2001, Munich, Germany.
69. Richat Abbas, Gregory Osgood, Terry Rivera-Schaub, James C. Kisicki, and Robert A. Baughman. A Clinical Drug-interaction Study to Evaluate Effect of Antacid Pre-treatment on the Absorption of Heparin and its Delivery Agent, SNAC, Following Oral Administration in Healthy Subjects. Presented at the Annual Meeting of the American Association of Pharmaceutical Scientists. Oct. 2001, Denver, CO.
70. Richat Abbas, Andrea Leone-Bay, Terry Rivera-Schaub, Shingai Majuru, James C. Kisicki, and Robert A. Baughman. An Open-label, Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of SNAD, an Oral Heparin Delivery Agent, when Administered Orally as SNAD Tablets or Heparin/SNAD Tablets to Healthy Male Volunteers. Presented at the Annual Meeting of the American Association of Pharmaceutical Scientists. Oct. 2001, Denver, CO.
71. Richat Abbas, Theresa Rivera-Schaub, Igor Rubets, Rajesh Agarwal and Robert A. Baughman. Clinical Pharmacokinetics and Absolute Bioavailability of the Oral Delivery Agent SNAC when Dosed Orally as SNAC/Heparin to Healthy Volunteers. Presented at the Pharmaceutical Congress of Americas, March 24-29, 2001, Orlando FL.
72. Andrea Leone-Bay, Theresa Rivera-Schaub, Shingai Majuru, Richat Abbas, James Kisicki, and Robert A. Baughman. PHASE I STUDY TO ASSESS THE SAFETY AND TOLERABILITY OF AN ORAL HEPARIN TABLET. Presented at the American Society of Hematology 2001 Annual Meeting. December 7 – 11, 2001, Orlando, FL.
73. Gu, Z., Tata, P. Zhou, D., Abbas, R., Wu, J., Lewis, N. J., and Bramer, S. L. A sensitive and specific LC-MS/MS method for the analysis of low levels of OPC-29030 and ten metabolites in human plasma and urine. Presented at the Annual Meeting of the American Association of Pharmaceutical Scientists. Nov. 15-19. 1998, San Francisco, CA. 
74. Abbas, R. and W. L. Hayton. A Physiologically Based Pharmacokinetic and Pharmacodynamic Model for Paraoxon in Rainbow Trout. Invited speaker at the international symposium, Annual Meeting of the American Chemical Society (ACS) March 28 – April 2, 1998, Dallas, TX.
75. Abbas, R., Bramer, S. L., Cowart, D., Adeyemo, O. M., Kitani, M., Miyamoto, G., and Browder, N. J. Interspecies Comparison of TOBORINONE Pharmacokinetics in Rats, Rabbits, Dogs, Monkeys, and Humans. Presented at the 37th Annual Meeting of the Society of Toxicology, March 1-5, 1998, Seattle, WA. 
76. Abbas, R., Flockhart, D. A., Thacker, D., Bramer, S. L., Cowart, D., and Browder, N. J. In vitro metabolism of toborinone by human liver cytochrome P450 isoforms. Presented at the 37th Annual Meeting of the Society of Toxicology, March 1-5, 1998, Seattle, WA.
77. Abbas, R. Tata, P. Bramer, S. L. Li, Y. X. Heitkamp, J. and Velagaleti, P. A LC-MS/MS METHOD FOR QUANTITATIVE ANALYSIS OF LOW LEVELS OF R(+) AND S(-) ENANTIOMERS OF OPC-41061 IN HUMAN SERUM. Presented at the 6th European International Society for the Study of Xenobiotics Meeting, June 30-July 3, 1997, Gothenburg, Sweden.
78. Abbas, R. Tata, P. Bramer, S. L. Li, Y. X. Heitkamp, J. and Velagaleti, P. A SENSITIVE AND SPECIFIC CHIRAL HPLC-MS/MS METHOD FOR QUANTITATIVE ANALYSIS OF LOW LEVELS OF R(+) AND S(-) ENANTIOMERS OF OPC-41061 IN HUMAN SERUM. Presented at the 12TH Annual Meeting of American Association of Pharmaceutical Scientists, Nov. 2-6, 1997. Boston, 
79. Abbas, R. Browder, N. J. Chow, P. Odomi, M. and Bramer, S. L. INTERSPECIES COMPARISON OF CILOSTAZOL PHARMACOKINETICS IN MICE, RATS, DOGS, MONKEYS, AND HUMANS. Presented at the 12TH Annual Meeting of American Association of Pharmaceutical Scientists, Nov. 2-6, 1997. Boston,   
80. Abbas, R., Seckel, C. S. and Fisher, J. W.: Determination of kinetic rate constants for chloral hydrate, trichloroethanol, trichloroacetate and dichloroacetate: a PBPK model approach. Presented at the 36th Annual Meeting of the Society of Toxicology, March 9-13, 1997, Cincinnati, OH.
81. R. Abbas, J. W. Fisher, R. K. Black, T. J. Janicki, and , K. MacMahan. Development of A Physiologically Based Pharmacokinetic (PBPK) Model for Tricholoroethylene and its Metabolites B6C3F1 Mice. Presented at the 35th Annual Meeting of the Society of Toxicology, March 10-14, 1996, Anaheim, CA.
82. Abbas, R., Fisher, J. W. Black, R. K. and Garrity, B. L. A Physiologically Based Pharmacokinetic Model to Describe Disposition of Chloral hydrate and Trichloroethanol in Mice. Presented at the International Congress of Toxicology – VII, July 2-6, 1995, Seattle, WA.
83. Abbas, R., Fisher, J. W., Black, R. K., Janicki, T. J. and Garrity, B. L. Disposition of Trichloroethylene and Its Metabolites in B6C3F1 Mice after Oral Administration. Presented at the 10TH Annual Meeting of American Association of Pharmaceutical Scientists, Nov. 5-9, 1995. Miami, FL. 
84. Abbas, R. and Hayton, W. L., In vivo Acetylcholinesterase Inhibition in Rainbow Trout after Water Exposure to Paraoxon. Presented at the 25th Annual Pharmaceutics Graduate Student Research Meeting, 1993, West Lafayette, Indiana.
85. Abbas, R. and Hayton, W. L., Paraoxon Tissue Distribution and AChE Inhibition in Rainbow Trout. Presented at the 8TH Annual Meeting of American Association of Pharmaceutical Scientists, Nov. 14-18, 1993, Lake Vuena Vista, FL.
86. Abbas, R., Schultz, I. R., Doddapaneni, S. and Hayton, W. L., 1992. Pharmacokinetics of Paraoxon in Rainbow Trout. Presented at the 31st Annual Meeting of the Society of Toxicology, Feb. 23-28, 1992, Seattle, WA.
источник:
http://www.meripet.com/Bio/RishatAbbas.htm
http://akademiye.org/en/wp-content/uploads/2013/05/Biography-Publications-of-Rishat-Abbas-Borhan-Aug-2013.pdf


Оставить комментарий


Подняться вверх
error: